Grifols to acquire Novartis' blood unit for $1.68 billion

Posted by David Bracken on November 11, 2013 

Grifols, the Spanish biotherapeutics company with a large presence in the Triangle, announced Monday that it is acquiring Novartis’ diagnostics business unit for $1.68 billion.

The acquisition includes a manufacturing plant in Emeryville, Calif. as well as offices in the U.S., Switzerland and Hong Kong.

Grifols employs several thousand people in the Triangle. In 2010, the company acquired Talecris, which is based in Research Triangle Park and has a drug-manufacturing facility in Clayton, for $3.4 billion.

Grifols and Talecris make medicine from blood plasma, used to treat a wide range of diseases, including hemophilia and various immune system deficiencies. Last year, Grifols invested $25 million expanding its Clayton facilities.

Grifols said it expects the acquisition of Novartis’ blood unit to increase annual revenue for its diagnostics division to nearly $1 billion. That division is expected to account for about 20 percent of the Barcelona-based company’s sales.

The deal is expected to close in the first half of next year.

News & Observer is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere in the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from profanity, hate speech, personal comments and remarks that are off point. Thank you for taking the time to offer your thoughts.

Commenting FAQs | Terms of Service